FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.
Summary
The FDA has granted approval for Rasonque, a new RAS inhibitor that targets the most common form of metastatic pancreatic cancer. This treatment offers hope to patients with advanced stages of the disease, arriving earlier than anticipated.
Comments (74 of ) ⌛